Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.7352W HIGH $20.70
Volume
108.01 K
Value Traded
7.16 M
Short % Float
54.78%
0%Week
0%1 Month
0%3 Month
0%6 Month
0%5 Year
-10.68%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.71 B
EPS (TTM)
-5.39
P/E Ratio
-3.55
Ent. Value
72.18 M
Total Shares
2.62 M
Float Shares
1.28 M
Insiders
99.12%
Institutions
0.85%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CHRN Catalyst Timeline
Dated clinical, regulatory and corporate events for Ekso Bionics Holdings, Inc.
Past FDA Catalysts and PDUFA Decisions
How CHRN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Ekso Bionics Holdings, Inc. is a services and tools company (CRO, lab tools or healthcare services). The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every CHRN program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Jones Jason COfficer (Chief Operating Officer) | Buy | 1,308 4,449 held | $11.85 | 03/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CHRN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in CHRN for Q2 2026. | ||||
CHRN Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CHRN ranks across every disease it competes in
Competitive Position is a premium feature
See how CHRN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCHRN News
About Ekso Bionics Holdings, Inc.
Headquarters3811 TURTLE CREEK BLVD., DALLAS, TX, 75219
Founded2005
BIOPHARMAWATCH ELITE PLUS
Trade the next CHRN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime